NASDAQ
MRUS

Merus BV

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Merus BV Stock Price

Vitals

Today's Low:
$23.88
Today's High:
$24.625
Open Price:
$23.9
52W Low:
$12.03
52W High:
$27.7
Prev. Close:
$23.95
Volume:
324852

Company Statistics

Market Cap.:
$1.38 billion
Book Value:
5.163
Revenue TTM:
$41.22 million
Operating Margin TTM:
-418.45%
Gross Profit TTM:
$-107838000
Profit Margin:
0%
Return on Assets TTM:
-26.67%
Return on Equity TTM:
-61.08%

Company Profile

Merus BV had its IPO on 2016-05-19 under the ticker symbol MRUS.

The company operates in the Healthcare sector and Biotechnology industry. Merus BV has a staff strength of 164 employees.

Stock update

Shares of Merus BV opened at $23.9 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $23.88 - $24.63, and closed at $24.39.

This is a +1.84% increase from the previous day's closing price.

A total volume of 324,852 shares were traded at the close of the day’s session.

In the last one week, shares of Merus BV have increased by +5.04%.

Merus BV's Key Ratios

Merus BV has a market cap of $1.38 billion, indicating a price to book ratio of 2.1479 and a price to sales ratio of 13.1869.

In the last 12-months Merus BV’s revenue was $41.22 million with a gross profit of $-107838000 and an EBITDA of $-170620000. The EBITDA ratio measures Merus BV's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Merus BV’s operating margin was -418.45% while its return on assets stood at -26.67% with a return of equity of -61.08%.

In Q2, Merus BV’s quarterly earnings growth was a positive 0% while revenue growth was a negative 17.4%.

Merus BV’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-3.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Merus BV’s profitability.

Merus BV stock is trading at a EV to sales ratio of 6.6505 and a EV to EBITDA ratio of -2.3717. Its price to sales ratio in the trailing 12-months stood at 13.1869.

Merus BV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$363.62 million
Total Liabilities
$65.85 million
Operating Cash Flow
$0
Capital Expenditure
$349000
Dividend Payout Ratio
0%

Merus BV ended 2024 with $363.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $363.62 million while shareholder equity stood at $257.41 million.

Merus BV ended 2024 with $0 in deferred long-term liabilities, $65.85 million in other current liabilities, 5099000.00 in common stock, $-669896000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $101.10 million and cash and short-term investments were $265.05 million. The company’s total short-term debt was $1,610,000 while long-term debt stood at $0.

Merus BV’s total current assets stands at $283.13 million while long-term investments were $46.50 million and short-term investments were $163.95 million. Its net receivables were $3.81 million compared to accounts payable of $7.60 million and inventory worth $12.22 million.

In 2024, Merus BV's operating cash flow was $0 while its capital expenditure stood at $349000.

Comparatively, Merus BV paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$24.39
52-Week High
$27.7
52-Week Low
$12.03
Analyst Target Price
$46.44

Merus BV stock is currently trading at $24.39 per share. It touched a 52-week high of $27.7 and a 52-week low of $27.7. Analysts tracking the stock have a 12-month average target price of $46.44.

Its 50-day moving average was $24.27 and 200-day moving average was $20.13 The short ratio stood at 18.34 indicating a short percent outstanding of 0%.

Around 840.5% of the company’s stock are held by insiders while 8385.9% are held by institutions.

Frequently Asked Questions About Merus BV

The stock symbol (also called stock or share ticker) of Merus BV is MRUS

The IPO of Merus BV took place on 2016-05-19

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Sunworks Inc (SUNW)
$0.75
0
+0.09%
WeWork Inc. (WE-WT)
$0.01
-0
-28.28%
$18.81
-0.34
-1.78%
$63.42
0.19
+0.3%
$4.28
0.03
+0.71%
$524.5
-16.35
-3.02%
$54.9
0
0%
$10.09
0.01
+0.05%
$46.52
-2.07
-4.26%
$339.45
22.25
+7.01%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Address

Yalelaan 62, Utrecht, Netherlands, 3584 CM